Bedoya-Toro Munera Maria E 4

Accession 0000905718-21-001112

CIK 0001853816other

Filed

Aug 16, 8:00 PM ET

Accepted

Aug 17, 12:51 PM ET

Size

29.7 KB

Accession

0000905718-21-001112

Form 4

Period: 2021-08-17

SVP, Regulatory Affairs

Transactions

Conversion
Series 1 Preferred Stock
2021-08-17−280,000→ 0 total(indirect: By Trust)
→ Common Stock (13,658 underlying)
Conversion
Common Stock
2021-08-17+19,512→ 48,186 total(indirect: By Trust)
Conversion
Series 1d Preferred Stock
2021-08-17−61,821→ 0 total(indirect: By Trust)
→ Common Stock (9,162 underlying)
Conversion
Series 1a Preferred Stock
2021-08-17−400,000→ 0 total(indirect: By Trust)
→ Common Stock (19,512 underlying)
Conversion
Series 1b Preferred Stock
2021-08-17−100,000→ 0 total(indirect: By Trust)
→ Common Stock (4,878 underlying)
Conversion
Series 1a Warrants
2021-08-17−100,000→ 0 total(indirect: By Trust)
From: 2016-11-15Exp: 2026-03-14→ Common Stock (4,878 underlying)
Conversion
Warrant to Purchase Common Stock
2021-08-17+4,878→ 4,878 total(indirect: By Trust)
Exercise: $20.50From: 2016-11-15Exp: 2026-03-14→ Common Stock (4,878 underlying)
Conversion
Common Stock
2021-08-17+9,162→ 28,674 total(indirect: By Trust)
Conversion
Common Stock
2021-08-17+4,878→ 53,064 total(indirect: By Trust)
Conversion
Common Stock
2021-08-17+17,421→ 70,485 total(indirect: By Trust)
Conversion
Common Stock
2021-08-17+13,658→ 84,143 total(indirect: By Trust)
Conversion
Series 1c Preferred Stock
2021-08-17−357,142→ 0 total(indirect: By Trust)
→ Common Stock (17,421 underlying)

Holdings

Footnotes (7)

[F1]The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.
[F2]The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date.
[F3]The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date.
[F4]The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date.
[F5]The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date.
[F6]The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO.
[F7]Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Documents

1 file

Dermata Therapeutics, Inc.

CIK 0001853816

Entity typeother